the ANRS CO21 " Extreme " Cohort (CODEX)
ConditionHIV Infection
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorANRS, Emerging Infectious Diseases
About this trial
A consortium of research teams has studied the immunovirological characteristics of these patients:
The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient infected with HIV-1 and not co-infected with HIV-2
Age ≥ 18 at enrollment
Able to give written consent
Covered by French Social Security
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
blood sampling
Biological/Vaccineblood sampling
Treatment groups
450 Participants
are divided into 1 treatment groupGroup A: Cohort studyOther 1 intervention
Trial outcomes
Primary outcomes
1
clinical and immuno-virological
Time frame
up to 5 yearsSecondary outcomes
1
mechanisms leading to the virus control and CD4 homeostasy with physiopathological studies
Time frame
up to 5 years2
impact of a prolonged untreated HIV infection,
Time frame
up to 5 years3
frequency of the "immunological escapes" (CD4 T cell decrease) or "virological escapes" (permanent or transient viral load increase)
Time frame
up to 5 years4
genetic characteristics of the patients and those of their viruses, the innate and adaptative immune responses directed against HIV and other viruses, the consequences of inflammation, and the characteristics of the loss of control
Time frame
up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov